In vitro, in silico and integrated strategies for the estimation of plasma protein binding. A review

Advanced Drug Delivery Reviews

Volumn 86, Issue , 2015, Pages 27-45

  Lambrinidis, George ^a   Vallianatou, Theodosia ^a   Tsantili Kakoulidou, Anna ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Human serum albumin; In silico predictions; Ligand based modeling; Plasma protein binding; Structure based modeling; 1 Acid glycoprotein

Indexed keywords

BIOCHEMISTRY; COMPUTATIONAL CHEMISTRY; CRYSTAL STRUCTURE; FORECASTING; GLYCOPROTEINS; LIGANDS; MOLECULAR GRAPHICS; PROTEINS;

ALPHA-1-ACID GLYCOPROTEINS (AGP); BIOANALYTICAL TECHNIQUES; HUMAN SERUM ALBUMINS; IN-SILICO; PLASMA PROTEIN BINDING; PROPERTIES OPTIMIZATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS; STRUCTURE-BASED;

DRUG INTERACTIONS;

AMITRIPTYLINE; AMLODIPINE; CHLORPROMAZINE; CURCUMIN; DISOPYRAMIDE; HUMAN SERUM ALBUMIN; IMATINIB; OROSOMUCOID; WARFARIN; DRUG; LIGAND; PLASMA PROTEIN; PROTEIN BINDING;

AFFINITY CHROMATOGRAPHY; BINDING AFFINITY; BINDING SITE; CHEMOMETRICS; COMPUTER MODEL; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; HUMAN; IN VITRO STUDY; MOLECULAR DOCKING; NONHUMAN; PLASMA PROTEIN BINDING; PREDICTION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SIMULATION; ULTRACENTRIFUGATION; ULTRAFILTRATION; BIOLOGICAL MODEL; COMPUTER SIMULATION; METABOLISM;

BLOOD PROTEINS; COMPUTER SIMULATION; HUMANS; LIGANDS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84937630310     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.03.011     Document Type: Review

References (220)

1. Oprea T.I. Property distribution of drug-related chemical databases. J. Comput. Aided Mol. Des. 2000, 14:251-264.
2. Di L., Kerns E.H. Application of pharmaceutical profiling assays for optimization of drug-like properties. Curr. Opin. Drug Discov. Dev. 2005, 8:495-504.
3. Hou T., Wang J., Zhang W., Wang W., Xu X. Recent advances in computational prediction of drug absorption and permeability in drug discovery. Curr. Med. Chem. 2006, 13:2653-2667.
4. Tian S., Li Y., Wang J., Zhang J., Hou T. ADME evaluation in drug discovery. 9. Prediction of oral bioavailability in humans based on molecular properties and structural fingerprints. Mol. Pharm. 2011, 8:841-851.
5. Hou T., Wang J., Zhang W., Xu X. ADME evaluation in drug discovery. 6. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules?. J. Chem. Inf. Model. 2007, 47:460-463.
6. Zhu J., Wang J., Yu H., Li Y., Hou T. Recent developments of in silico predictions of oral bioavailability. Comb. Chem. High Throughput Screen. 2011, 14:362-374.
7. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 2004, 3:711-715.
8. Smith D.A., van de Waterbeemd H. Pharmacokinetics and metabolism in early drug discovery. Curr. Opin. Chem. Biol. 1999, 3:373-378.
9. Ito K., Iwatsubo T., Kanamitsu S., Nakajima Y., Sugiyama Y. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu. Rev. Pharmacol. Toxicol. 1998, 38:461-499.
10. Rowley M., Kulagowski J.J., Watt A.P., Rathbone D., Stevenson G.I., Carling R.W., Baker R., Marshall G.R., Kemp J.A., Foster A.C., Grimwood S., Hargreaves R., Hurley C., Saywell K.L., Tricklebank M.D., Leeson P.D. Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. J. Med. Chem. 1997, 40:4053-4068.
11. Rogge M.C., Taft D.R. Preclinical drug development 2010, Informa Healthcare, New York. 2nd ed.
12. Smith D.A., Di L., Kerns E.H. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat. Rev. Drug Discov. 2010, 9:929-939.
13. Elsadek B., Kratz F. Impact of albumin on drug delivery-new applications on the horizon. J. Control. Release 2012, 157:4-28.
14. Rolan P.E. Plasma protein binding displacement interactions-why are they still regarded as clinically important?. Br. J. Clin. Pharmacol. 1994, 37:125-128.
15. Benet L.Z., Hoener B.A. Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther. 2002, 71:115-121.
16. Heuberger J., Schmidt S., Derendorf H. When is protein binding important?. J. Pharm. Sci. 2013, 102:3458-3467.
17. DeVane C.L. Clinical significance of drug binding, protein binding, and binding displacement drug interactions. Psychopharmacol. Bull. 2002, 36:5-21.
18. Pellegatti M., Pagliarusco S., Solazzo L., Colato D. Plasma protein binding and blood-free concentrations: which studies are needed to develop a drug?. Expert Opin. Drug Metab. Toxicol. 2011, 7:1009-1020.
19. Buscher B., Laakso S., Mascher H., Pusecker K., Doig M., Dillen L., Wagner-Redeker W., Pfeifer T., Delrat P., Timmerman P. Bioanalysis for plasma protein binding studies in drug discovery and drug development: views and recommendations of the European Bioanalysis Forum. Bioanalysis 2014, 6:673-682.
20. Lee B.L., Sachdeva M., Chambers H.F. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob. Agents Chemother. 1991, 35:2505-2508.
21. Vallner J.J. Binding of drugs by albumin and plasma protein. J. Pharm. Sci. 1977, 66:447-465.
22. Peters T. All About Albumin: Biochemistry, Genetics, and Medical Applications 1996, Academic Press, San Diego.
23. Evans T.W. Review article: albumin as a drug-biological effects of albumin unrelated to oncotic pressure. Aliment. Pharmacol. Ther. 2002, 16(Suppl. 5):6-11.
24. Mendez C.M., McClain C.J., Marsano L.S. Albumin therapy in clinical practice. Nutr. Clin. Pract. 2005, 20:314-320.
25. Stamler J.S., Jaraki O., Osborne J., Simon D.I., Keaney J., Vita J., Singel D., Valeri C.R., Loscalzo J. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:7674-7677.
26. Nobeli I., Favia A.D., Thornton J.M. Protein promiscuity and its implications for biotechnology. Nat. Biotechnol. 2009, 27:157-167.
27. Pehourcq F.D., Radouane A., Labat L., Bannwarth B. Influence of lipophilicity on the protein binding affinity of cephalosporins. Pharm. Res. 1995, 12:1535-1538.
28. Leo A., Hansch C., Elkins D. Partition coefficients and their uses. Chem. Rev. 1971, 71:525-616.
29. Lejon S., Frick I.M., Bjorck L., Wikstrom M., Svensson S. Crystal structure and biological implications of a bacterial albumin binding module in complex with human serum albumin. J. Biol. Chem. 2004, 279:42924-42928.
30. Sugio S., Kashima A., Mochizuki S., Noda M., Kobayashi K. Crystal structure of human serum albumin at 2.5A resolution. Protein Eng. 1999, 12:439-446.
31. Curry S., Brick P., Franks N.P. Fatty acid binding to human serum albumin: new insights from crystallographic studies. Biochim. Biophys. Acta 1999, 1441:131-140.
32. Carter D.C., Ho J.X. Structure of serum albumin. Adv. Protein Chem. 1994, 45:153-203.
33. Deeb O., Rosales-Hernandez M.C., Gomez-Castro C., Garduno-Juarez R., Correa-Basurto J. Exploration of human serum albumin binding sites by docking and molecular dynamics flexible ligand-protein interactions. Biopolymers 2010, 93:161-170.
34. Kratochwil N.A., Huber W., Muller F., Kansy M., Gerber P.R. Predicting plasma protein binding of drugs: a new approach. Biochem. Pharmacol. 2002, 64:1355-1374.
35. Petitpas I., Bhattacharya A.A., Twine S., East M., Curry S. Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I. J. Biol. Chem. 2001, 276:22804-22809.
36. Sudlow G., Birkett D.J., Wade D.N. The characterization of two specific drug binding sites on human serum albumin. Mol. Pharmacol. 1975, 11:824-832.
37. Sjoholm I., Ekman B., Kober A., Ljungstedt-Pahlman I., Seiving B., Sjodin T. Binding of drugs to human serum albumin: XI. The specificity of three binding sites as studied with albumin immobilized in microparticles. Mol. Pharmacol. 1979, 16:767-777.
38. Petitpas I., Petersen C.E., Ha C.E., Bhattacharya A.A., Zunszain P.A., Ghuman J., Bhagavan N.V., Curry S. Structural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemia. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6440-6445.
39. Ghuman J., Zunszain P.A., Petitpas I., Bhattacharya A.A., Otagiri M., Curry S. Structural basis of the drug-binding specificity of human serum albumin. J. Mol. Biol. 2005, 353:38-52.
40. Curry S. Lessons from the crystallographic analysis of small molecule binding to human serum albumin. Drug Metab. Pharmacokinet. 2009, 24:342-357.
41. Zsila F. Subdomain IB is the third major drug binding region of human serum albumin: toward the three-sites model. Mol. Pharm. 2013, 10:1668-1682.
42. Zunszain P.A., Ghuman J., Komatsu T., Tsuchida E., Curry S. Crystal structural analysis of human serum albumin complexed with hemin and fatty acid. BMC Struct. Biol. 2003, 3:6.
43. Zunszain P.A., Ghuman J., McDonagh A.F., Curry S. Crystallographic analysis of human serum albumin complexed with 4Z,15E-bilirubin-IXalpha. J. Mol. Biol. 2008, 381:394-406.
44. Zhu L., Yang F., Chen L., Meehan E.J., Huang M. A new drug binding subsite on human serum albumin and drug-drug interaction studied by X-ray crystallography. J. Struct. Biol. 2008, 162:40-49.
45. Ryan A.J., Ghuman J., Zunszain P.A., Chung C.W., Curry S. Structural basis of binding of fluorescent, site-specific dansylated amino acids to human serum albumin. J. Struct. Biol. 2011, 174:84-91.
46. Guo S., Shi X., Yang F., Chen L., Meehan E.J., Bian C., Huang M. Structural basis of transport of lysophospholipids by human serum albumin. Biochem. J. 2009, 423:23-30.
47. Fasano M., Curry S., Terreno E., Galliano M., Fanali G., Narciso P., Notari S., Ascenzi P. The extraordinary ligand binding properties of human serum albumin. IUBMB Life 2005, 57:787-796.
48. Ahmed-Ouameur A., Diamantoglou S., Sedaghat-Herati M.R., Nafisi S., Carpentier R., Tajmir-Riahi H.A. The effects of drug complexation on the stability and conformation of human serum albumin: protein unfolding. Cell Biochem. Biophys. 2006, 45:203-213.
49. Ascenzi P., Bocedi A., Notari S., Fanali G., Fesce R., Fasano M. Allosteric modulation of drug binding to human serum albumin. Mini Rev. Med. Chem. 2006, 6:483-489.
50. Varshney A., Sen P., Ahmad E., Rehan M., Subbarao N., Khan R.H. Ligand binding strategies of human serum albumin: how can the cargo be utilized?. Chirality 2010, 22:77-87.
51. Ascenzi P., Fasano M. Allostery in a monomeric protein: the case of human serum albumin. Biophys. Chem. 2010, 148:16-22.
52. Gupta D., Lis C.G. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr. J. 2010, 9:69.
53. Koga M., Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocr. J. 2010, 57:751-762.
54. Sbarouni E., Georgiadou P., Voudris V. Ischemia modified albumin changes - review and clinical implications. Clin. Chem. Lab. Med. 2011, 49:177-184.
55. Guerin-Dubourg A., Catan A., Bourdon E., Rondeau P. Structural modifications of human albumin in diabetes. Diabetes Metab. 2012, 38:171-178.
56. Goto T., Murata K., Lee S.H., Oe T. Complete amino acid sequencing and immunoaffinity clean-up can facilitate screening of various chemical modifications on human serum albumin. Anal. Bioanal. Chem. 2013, 405:7383-7395.
57. Lapolla A., Molin L., Traldi P. Protein glycation in diabetes as determined by mass spectrometry. Int. J. Endocrinol. 2013, 2013:412103.
58. Osaki F., Goto T., Lee S.H., Oe T. Predicted multiple selected reaction monitoring to screen activated drug-mediated modifications on human serum albumin. Anal. Biochem. 2014, 449:59-67.
59. Switzar L., Giera M., Lingeman H., Irth H., Niessen W.M. Protein digestion optimization for characterization of drug-protein adducts using response surface modeling. J. Chromatogr. A 2011, 1218:1715-1723.
60. Fournier T., Medjoubi N.N., Porquet D. Alpha-1-acid glycoprotein. Biochim. Biophys. Acta 2000, 1482:157-171.
61. Israili Z.H., Dayton P.G. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab. Rev. 2001, 33:161-235.
62. Kopecky V., Ettrich R., Hofbauerova K., Baumruk V. Structure of human alpha1-acid glycoprotein and its high-affinity binding site. Biochem. Biophys. Res. Commun. 2003, 300:41-46.
63. Otagiri M. A molecular functional study on the interactions of drugs with plasma proteins. Drug Metab. Pharmacokinet. 2005, 20:309-323.
64. Herve F., Duche J.C., d'Athis P., Marche C., Barre J., Tillement J.P. Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics 1996, 6:403-415.
65. Paxton J.W. Alpha 1-acid glycoprotein and binding of basic drugs. Methods Find. Exp. Clin. Pharmacol. 1983, 5:635-648.
66. Dente L., Pizza M.G., Metspalu A., Cortese R. Structure and expression of the genes coding for human alpha 1-acid glycoprotein. EMBO J. 1987, 6:2289-2296.
67. Herve F., Gomas E., Duche J.C., Tillement J.P. Fractionation of the genetic variants of human alpha 1-acid glycoprotein in the native form by chromatography on an immobilized copper(II) affinity adsorbent. Heterogeneity of the separate variants by isoelectrofocusing and by concanavalin A affinity chromatography. J. Chromatogr. 1993, 615:47-57.
68. Budai L., Ozohanics O., Ludanyi K., Drahos L., Kremmer T., Krenyacz J., Vekey K. Investigation of genetic variants of alpha-1 acid glycoprotein by ultra-performance liquid chromatography-mass spectrometry. Anal. Bioanal. Chem. 2009, 393:991-998.
69. Hochepied T., Berger F.G., Baumann H., Libert C. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev. 2003, 14:25-34.
70. Lacki J.K., Klama K., Samborski W., Mackiewicz S.H., Muller W. Comparison of microheterogeneity of alpha-1-acid-glycoprotein in serum and synovial fluid from rheumatoid arthritis patients. Clin. Rheumatol. 1994, 13:598-604.
71. Fitos I., Visy J., Zsila F., Mady G., Simonyi M. Selective binding of imatinib to the genetic variants of human alpha1-acid glycoprotein. Biochim. Biophys. Acta 2006, 1760:1704-1712.
72. Nishi K., Ono T., Nakamura T., Fukunaga N., Izumi M., Watanabe H., Suenaga A., Maruyama T., Yamagata Y., Curry S., Otagiri M. Structural insights into differences in drug-binding selectivity between two forms of human alpha1-acid glycoprotein genetic variants, the A and F1*S forms. J. Biol. Chem. 2011, 286:14427-14434.
73. Eap C.B., Cuendet C., Baumann P. Binding of amitriptyline to alpha 1-acid glycoprotein and its variants. J. Pharm. Pharmacol. 1988, 40:767-770.
74. Eap C.B., Cuendet C., Baumann P. Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha 1-acid glycoprotein. Clin. Pharmacol. Ther. 1990, 47:338-346.
75. Schonfeld D.L., Ravelli R.B., Mueller U., Skerra A. The 1.8-A crystal structure of alpha1-acid glycoprotein (Orosomucoid) solved by UV RIP reveals the broad drug-binding activity of this human plasma lipocalin. J. Mol. Biol. 2008, 384:393-405.
76. Johnson D.A., Smith K.D. The efficacy of certain anti-tuberculosis drugs is affected by binding to alpha-1-acid glycoprotein. Biomed. Chromatogr. 2006, 20:551-560.
77. Azad M.A., Huang J.X., Cooper M.A., Roberts K.D., Thompson P.E., Nation R.L., Li J., Velkov T. Structure-activity relationships for the binding of polymyxins with human alpha-1-acid glycoprotein. Biochem. Pharmacol. 2012, 84:278-291.
78. Jolliet-Riant P., Boukef M.F., Duche J.C., Simon N., Tillement J.P. The genetic variant A of human alpha 1-acid glycoprotein limits the blood to brain transfer of drugs it binds. Life Sci. 1998, 62:L219-L226.
79. Matsuo K., Namatame H., Taniguchi M., Gekko K. Membrane-induced conformational change of alpha1-acid glycoprotein characterized by vacuum-ultraviolet circular dichroism spectroscopy. Biochemistry 2009, 48:9103-9111.
80. Nishi K., Maruyama T., Halsall H.B., Handa T., Otagiri M. Binding of alpha1-acid glycoprotein to membrane results in a unique structural change and ligand release. Biochemistry 2004, 43:10513-10519.
81. Taguchi K., Nishi K., Chuang V.T.G., Maruyama T., Otagiri M. Molecular aspects of human alpha-1 acid glycoprotein - structure and function, in Acute Phase Proteins 2013, New York. S. Janciauskiene (Ed.).
82. Szakacs G., Varadi A., Ozvegy-Laczka C., Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov. Today 2008, 13:379-393.
83. Zsila F. Overlapping ligand specificity of P-glycoprotein and serum alpha(1)-acid glycoprotein: evidences and potential implications. Curr. Drug Metab. 2007, 8:563-593.
84. Lin J., Cocchetto D., Duggan D. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin. Pharmacokinet. 1987, 12:402-432.
85. Tasker R.A., Nakatsu K. Factors affecting ultrafiltration-assessed values for drug binding. Clin. Chem. 1982, 28:1244-1246.
86. Zini R. Methods in drug protein binding analysis 1991, Elsevier Science Pub. Co., Amsterdam; New York, NY, USA.
87. Vuignier K., Schappler J., Veuthey J.L., Carrupt P.A., Martel S. Drug-protein binding: a critical review of analytical tools. Anal. Bioanal. Chem. 2010, 398:53-66.
88. Vuignier K., Veuthey J.L., Carrupt P.A., Schappler J. Global analytical strategy to measure drug-plasma protein interactions: from high-throughput to in-depth analysis. Drug Discov. Today 2013, 18:1030-1034.
89. Waters N.J., Jones R., Williams G., Sohal B. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J. Pharm. Sci. 2008, 97:4586-4595.
90. Banker M.J., Clark T.H., Williams J.A. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J. Pharm. Sci. 2003, 92:967-974.
91. Kariv I., Cao H., Oldenburg K.R. Development of a high throughput equilibrium dialysis method. J. Pharm. Sci. 2001, 90:580-587.
92. Vuignier K., Veuthey J.L., Carrupt P.A., Schappler J. Characterization of drug-protein interactions by capillary electrophoresis hyphenated to mass spectrometry. Electrophoresis 2012, 33:3306-3315.
93. Hage D.S., Tweed S.A. Recent advances in chromatographic and electrophoretic methods for the study of drug-protein interactions. J. Chromatogr. B Biomed. Sci. Appl. 1997, 699:499-525.
94. Martinez-Pla J.J., Sagrado S., Villaneuva-Camanas R.M., Medina-Hernandez M.J. Retention-property relationships of anticonvulsant drugs by biopartitioning micellar chromatography. J. Chromatogr. B Biomed. Sci. Appl. 2001, 757:89-99.
95. Parikh H.H., McElwain K., Balasubramanian V., Leung W., Wong D., Morris M.E., Ramanathan M. A rapid spectrofluorimetric technique for determining drug-serum protein binding suitable for high-throughput screening. Pharm. Res. 2000, 17:632-637.
96. Jia H., Yang G., Li Z., Xin P., Zhao Y., Chen Y. Micellar liquid chromatography with dodecyl dimethyl betaine as an in vitro method for prediction of protein-drug binding. J. Chromatogr. A 2007, 1143:88-97.
97. Hadjmohammadi M., Salary M. Biopartitioning micellar chromatography with sodium dodecyl sulfate as a pseudo alpha(1)-acid glycoprotein to the prediction of protein-drug binding. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2013, 912:50-55.
98. Klotz I.M. Physiochemical aspects of drug-protein interactions: a general perspective. Ann. N. Y. Acad. Sci. 1973, 226:18-35.
99. Zhang G., Wang L., Pan J. Probing the binding of the flavonoid diosmetin to human serum albumin by multispectroscopic techniques. J. Agric. Food Chem. 2012, 60:2721-2729.
100. Jali B.R., Kuang Y., Neamati N., Baruah J.B. Selective binding of naphthoquinone derivatives to serum albumin proteins and their effects on cytotoxicity. Chem. Biol. Interact. 2014, 214:10-17.
101. Meti M.D., Byadagi K.S., Nandibewoor S.T., Joshi S.D., More U.A., Chimatadar S.A. In vitro studies on the interaction between human serum albumin and fosfomycin disodium salt, an antibiotic drug by multi-spectroscopic and molecular docking methods. Mol. Biol. Rep. 2014, 41:2377-2387.
102. Epps D.E., Raub T.J., Caiolfa V., Chiari A., Zamai M. Determination of the affinity of drugs toward serum albumin by measurement of the quenching of the intrinsic tryptophan fluorescence of the protein. J. Pharm. Pharmacol. 1999, 51:41-48.
103. Gustafsson S.S., Vrang L., Terelius Y., Danielson U.H. Quantification of interactions between drug leads and serum proteins by use of "binding efficiency". Anal. Biochem. 2011, 409:163-175.
104. Rich R.L., Myszka D.G. Why you should be using more SPR biosensor technology. Drug Discov. Today Technol. 2004, 1:301-308.
105. Huber W., Mueller F. Biomolecular interaction analysis in drug discovery using surface plasmon resonance technology. Curr. Pharm. Des. 2006, 12:3999-4021.
106. Lu X., Ning B., He D., Huang L., Yue X., Zhang Q., Huang H., Liu Y., He L., Ouyang J. High throughput screening of high-affinity ligands for proteins with anion-binding sites using desorption electrospray ionization (DESI) mass spectrometry. J. Am. Soc. Mass Spectrom. 2014, 25:454-463.
107. Law V., Knox C., Djoumbou Y., Jewison T., Guo A.C., Liu Y., Maciejewski A., Arndt D., Wilson M., Neveu V., Tang A., Gabriel G., Ly C., Adamjee S., Dame Z.T., Han B., Zhou Y., Wishart D.S. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014, 42:D1091-D1097.
108. Dollery C.T. Therapeutic Drugs 1999, Churchill Livingstone, Edinburgh; New York. 2nd ed.
109. Goodman L.S., Gilman A., Hardman J.G., Gilman A.G., Limbird L.E. Goodman & Gilman's the Pharmacological Basis of Therapeutics 1996, McGraw-Hill, Health Professions Division, New York. 9th ed.
110. Southan C., Varkonyi P., Muresan S. Quantitative assessment of the expanding complementarity between public and commercial databases of bioactive compounds. J. Cheminformatics 2009, 1:10.
111. Williams A.J. A perspective of publicly accessible/open-access chemistry databases. Drug Discov. Today 2008, 13:495-501.
112. Williams A.J., Harland L., Groth P., Pettifer S., Chichester C., Willighagen E.L., Evelo C.T., Blomberg N., Ecker G., Goble C., Mons B. Open PHACTS: semantic interoperability for drug discovery. Drug Discov. Today 2012, 17:1188-1198.
113. Wan H., Bergström F. High throughput screening of drug-protein binding in drug discovery. J. Liq. Chromatogr. Relat. Technol. 2007, 30:681-700.
114. Hage D.S., Austin J. High-performance affinity chromatography and immobilized serum albumin as probes for drug- and hormone-protein binding. J. Chromatogr. B Biomed. Sci. Appl. 2000, 739:39-54.
115. Noctor T.A., Diaz-Perez M.J., Wainer I.W. Use of a human serum albumin-based stationary phase for high-performance liquid chromatography as a tool for the rapid determination of drug-plasma protein binding. J. Pharm. Sci. 1993, 82:675-676.
116. Chrysanthakopoulos M., Tsopelas F., Tsantili-Kakoulidou A. Biomimetic chromatography: a useful tool in the drug discovery process. Advances in Chromatography 2013, vol. 51. CRC Press. E. Grushka, Nelu (Eds.).
117. Ashton D.S., Beddell C.R., Cockerill G.S., Gohil K., Gowrie C., Robinson J.E., Slater M.J., Valko K. Binding measurements of indolocarbazole derivatives to immobilised human serum albumin by high-performance liquid chromatography. J. Chromatogr. B Biomed. Appl. 1996, 677:194-198.
118. Nakano N.I., Shimamori Y., Yamaguchi S. Binding capacities of human serum albumin monomer and dimer by continuous frontal affinity chromatography. J. Chromatogr. 1982, 237:225-232.
119. Noctor T.A., Pham C.D., Kaliszan R., Wainer I.W. Stereochemical aspects of benzodiazepine binding to human serum albumin. I. Enantioselective high performance liquid affinity chromatographic examination of chiral and achiral binding interactions between 1,4-benzodiazepines and human serum albumin. Mol. Pharmacol. 1992, 42:506-511.
120. Schill G., Wainer I.W., Barkan S.A. Chiral separations of cationic and anionic drugs on an alpha 1-acid glycoprotein-bonded stationary phase (EnantioPac). II. Influence of mobile phase additives and pH on chiral resolution and retention. J. Chromatogr. 1986, 365:73-88.
121. Xuan H., Hage D.S. Immobilization of alpha(1)-acid glycoprotein for chromatographic studies of drug-protein binding. Anal. Biochem. 2005, 346:300-310.
122. Valko K. Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution. J. Chromatogr. A 2004, 1037:299-310.
123. Valko K., Nunhuck S., Bevan C., Abraham M.H., Reynolds D.P. Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. J. Pharm. Sci. 2003, 92:2236-2248.
124. Reilly J., Etheridge D., Everatt B., Jiang Z., Aldcroft C., Wright P., Clemens I., Cox B., Press N.J., Watson S., Porter D., Springer C., Fairhurst R.A. Studies in drug albumin binding using HSA and RSA affinity methods. J. Liq. Chromatogr. Relat. Technol. 2011, 34:317-327.
125. Chrysanthakopoulos M., Giaginis C., Tsantili-Kakoulidou A. Retention of structurally diverse drugs in human serum albumin chromatography and its potential to simulate plasma protein binding. J. Chromatogr. A 2010, 1217:5761-5768.
126. Jewell R.C., Brouwer K.L., McNamara P.J. Alpha 1-acid glycoprotein high-performance liquid chromatography column (EnantioPAC) as a screening tool for protein binding. J. Chromatogr. 1989, 487:257-264.
127. Chrysanthakopoulos M., Vallianatou T., Giaginis C., Tsantili-Kakoulidou A. Investigation of the retention behavior of structurally diverse drugs on alpha(1) acid glycoprotein column: insight on the molecular factors involved and correlation with protein binding data. Eur. J. Pharm. Sci. 2014, 60:24-31.
128. Rapti A. Evaluation of a1-acid glycoprotein (AGP) binding measurements by high performance liuid chromatography and ultrafiltration methods. Project Report Drug Discovery 2006, University of London, London, (Msc School of Pharmacy).
129. Valkó K.r. Physicochemical and Biomimetic Properties in Drug Discovery: Chromatographic Techniques for Lead Optimization 2014, Wiley, New York.
130. Kaliszan R., Nasal A., Turowski M. Binding site for basic drugs on alpha 1-acid glycoprotein as revealed by chemometric analysis of biochromatographic data. Biomed. Chromatogr. 1995, 9:211-215.
131. Vuignier K., Guillarme D., Veuthey J.L., Carrupt P.A., Schappler J. High performance affinity chromatography (HPAC) as a high-throughput screening tool in drug discovery to study drug-plasma protein interactions. J. Pharm. Biomed. Anal. 2013, 74:205-212.
132. Valko K. HPLC based property measurements of drug discovery compounds to predict in vivo drug distribution and aid lead optimisation. 1st World Conference on Physico-Chemical Methods in Drug Discovery and Development Sep 27,2009-Oct 01,2009 Hotel Park, Rovinj, Croatia 2009, (http://www.iapchem.org/lectures/Rovinj%202009%20klv%20with%20copyright.pdf).
133. van de Waterbeemd H. Which in vitro screens guide the prediction of oral absorption and volume of distribution?. Basic Clin. Pharmacol. Toxicol. 2005, 96:162-166.
134. Hall M.L., Jorgensen W.L., Whitehead L. Automated ligand- and structure-based protocol for in silico prediction of human serum albumin binding. J. Chem. Inf. Model. 2013, 53:907-922.
135. Vallianatou T., Lambrinidis G., Tsantili-Kakoulidou A. In silico prediction of human serum albumin binding for drug leads. Expert Opin. Drug Discov. 2013, 8:583-595.
136. Markuszewski M., Kaliszan R. Quantitative structure-retention relationships in affinity high-performance liquid chromatography. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2002, 768:55-66.
137. Ashton D.S., Beddell C., Ray A.D., Valkó K. Quantitative structure-retention relationships of acyclovir esters using immobilised albumin high-performance liquid chromatography and reversed-phase high-performance liquid chromatography. J. Chromatogr. A 1995, 707:367-372.
138. Aureli L., Cruciani G., Cesta M.C., Anacardio R., De Simone L., Moriconi A. Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach. J. Med. Chem. 2005, 48:2469-2479.
139. Kaliszan R., Noctor T.A.G., Wainer I.W. Quantitative structure-enantioselective retention relationships for the chromatography of 1,4-benzodiazepines on a human serum albumin based HPLC chiral stationary phase: An approach to the computational prediction of retention and enantioselectivity. Chromatographia 1992, 33:546-550.
140. Tropsha A. Recent trends in statistical QSAR modeling of environmental chemical toxicity. EXS 2012, 101:381-411.
141. Milano Chemometrics and QSAR Research Group, Talete, Milano, Italy http://www.disat.unimib.it/chm/Dragon.htm.
142. CODESSA PRO, University of Florida http://www.codessa-pro.com/descriptors/index.htm.
143. Abraham M.H., Chadha H.S., Whiting G.S., Mitchell R.C. Hydrogen bonding. 32. An analysis of water-octanol and water-alkane partitioning and the delta log P parameter of seiler. J. Pharm. Sci. 1994, 83:1085-1100.
144. Todeschini R., Consonni V. R-Z. Handbook of Molecular Descriptors 2008, 366-510. Wiley-VCH Verlag GmbH.
145. Chirico N., Gramatica P. Real external predictivity of QSAR models. Part 2. New intercomparable thresholds for different validation criteria and the need for scatter plot inspection. J. Chem. Inf. Model. 2012, 52:2044-2058.
146. Roy K., Mitra I., Kar S., Ojha P.K., Das R.N., Kabir H. Comparative studies on some metrics for external validation of QSPR models. J. Chem. Inf. Model. 2012, 52:396-408.
147. Tropsha A., Gramatica P., Gombar V.K. The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb. Sci. 2003, 22:69-77.
148. Stanforth R.W., Kolossov E., Mirkin B. A measure of domain of applicability for QSAR modelling based on intelligent K-means clustering. QSAR Comb. Sci. 2007, 26:837-844.
149. Rodgers S.L., Davis A.M., van de Waterbeemd H. Time-series QSAR analysis of human plasma protein binding data. QSAR Comb. Sci. 2007, 26:511-521.
150. Hertzberg R.P., Pope A.J. High-throughput screening: new technology for the 21st century. Curr. Opin. Chem. Biol. 2000, 4:445-451.
151. Colmenarejo G. In silico prediction of drug-binding strengths to human serum albumin. Med. Res. Rev. 2003, 23:275-301.
152. Lobell M., Sivarajah V. In silico prediction of aqueous solubility, human plasma protein binding and volume of distribution of compounds from calculated pKa and AlogP98 values. Mol. Divers. 2003, 7:69-87.
153. Klopman G. The MultiCASE program II. Baseline activity identification algorithm (BAIA). J. Chem. Inf. Comput. Sci. 1998, 38:78-81.
154. Saiakhov R., Stefan L., Klopman G. Multiple computer-automated structure evaluation model of the plasma protein binding affinity of diverse drugs. Perspect. Drug Discov. Des. 2000, 19:133-155.
155. Yamazaki K., Kanaoka M. Computational prediction of the plasma protein-binding percent of diverse pharmaceutical compounds. J. Pharm. Sci. 2004, 93:1480-1494.
156. Chrysanthakopoulos M., Koletsou A., Nicolaou I., Demopoulos V.J., Tsantili-Kakoulidou A. Lipophilicity studies on pyrrolyl-acetic acid derivatives. Experimental versus predicted logP values in relationship with aldose reductase inhibitory activity. QSAR Comb. Sci. 2009, 28:551-560.
157. Colmenarejo G., Alvarez-Pedraglio A., Lavandera J.L. Cheminformatic models to predict binding affinities to human serum albumin. J. Med. Chem. 2001, 44:4370-4378.
158. Hall L.M., Hall L.H., Kier L.B. Modeling drug albumin binding affinity with e-state topological structure representation. J. Chem. Inf. Comput. Sci. 2003, 43:2120-2128.
159. Estrada E., Uriarte E., Molina E., Simon-Manso Y., Milne G.W. An integrated in silico analysis of drug-binding to human serum albumin. J. Chem. Inf. Model. 2006, 46:2709-2724.
160. Deeb O., Hemmateenejad B. ANN-QSAR model of drug-binding to human serum albumin. Chem. Biol. Drug Des. 2007, 70:19-29.
161. Gunturi S.B., Narayanan R., Khandelwal A. In silico ADME modelling 2: computational models to predict human serum albumin binding affinity using ant colony systems. Bioorg. Med. Chem. 2006, 14:4118-4129.
162. Moda T.L., Montanari C.A., Andricopulo A.D. In silico prediction of human plasma protein binding using hologram QSAR. Lett. Drug Des. Discov. 2007, 4:502-509.
163. Votano J.R., Parham M., Hall L.M., Hall L.H., Kier L.B., Oloff S., Tropsha A. QSAR modeling of human serum protein binding with several modeling techniques utilizing structure-information representation. J. Med. Chem. 2006, 49:7169-7181.
164. Wen Y., Liu H., Luan F., Gao Y. Application of quantitative structure-activity relationship to the determination of binding constant based on fluorescence quenching. J. Lumin. 2011, 131:126-133.
165. Ghafourian T., Amin Z. QSAR models for the prediction of plasma protein binding. BioImpacts 2013, 3:21-27.
166. Moda T.L., Torres L.G., Carrara A.E., Andricopulo A.D. PK/DB: database for pharmacokinetic properties and predictive in silico ADME models. Bioinformatics 2008, 24:2270-2271.
167. Zhu X.W., Sedykh A., Zhu H., Liu S.S., Tropsha A. The use of pseudo-equilibrium constant affords improved QSAR models of human plasma protein binding. Pharm. Res. 2013, 30:1790-1798.
168. Tropsha A. Best practices for QSAR model development, validation, and exploitation. Mol. Inform. 2010, 29:476-488.
169. Rodgers S.L., Davis A.M., Tomkinson N.P., van de Waterbeemd H. Predictivity of simulated ADME AutoQSAR models over time. Mol. Inform. 2011, 30:256-266.
170. Cartmell J., Enoch S., Krstajic D., Leahy D.E. Automated QSPR through competitive workflow. J. Comput. Aided Mol. Des. 2005, 19:821-833.
171. Herve F., Caron G., Duche J.C., Gaillard P., Abd Rahman N., Tsantili-Kakoulidou A., Carrupt P.A., d'Athis P., Tillement J.P., Testa B. Ligand specificity of the genetic variants of human alpha1-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant. Mol. Pharmacol. 1998, 54:129-138.
172. Taheri S., Cogswell L.P., Gent A., Strichartz G.R. Hydrophobic and ionic factors in the binding of local anesthetics to the major variant of human alpha1-acid glycoprotein. J. Pharmacol. Exp. Ther. 2003, 304:71-80.
173. Barbato F., di Martino G., Grumetto L., La Rotonda M.I. Retention of quinolones on human serum albumin and alpha1-acid glycoprotein HPLC columns: relationships with different scales of lipophilicity. Eur. J. Pharm. Sci. 2007, 30:211-219.
174. He X.M., Carter D.C. Atomic structure and chemistry of human serum albumin. Nature 1992, 358:209-215.
175. Oganesyan V., Damschroder M.M., Cook K.E., Li Q., Gao C., Wu H., Dall'Acqua W.F. Structural insights into neonatal Fc receptor-based recycling mechanisms. J. Biol. Chem. 2014, 289:7812-7824.
176. Schmidt M.M., Townson S.A., Andreucci A.J., King B.M., Schirmer E.B., Murillo A.J., Dombrowski C., Tisdale A.W., Lowden P.A., Masci A.L., Kovalchin J.T., Erbe D.V., Wittrup K.D., Furfine E.S., Barnes T.M. Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface. Structure 2013, 21:1966-1978.
177. Almogren A., Furtado P.B., Sun Z., Perkins S.J., Kerr M.A. Purification, properties and extended solution structure of the complex formed between human immunoglobulin A1 and human serum albumin by scattering and ultracentrifugation. J. Mol. Biol. 2006, 356:413-431.
178. Lejon S., Cramer J.F., Nordberg P. Structural basis for the binding of naproxen to human serum albumin in the presence of fatty acids and the GA module. Acta Crystallogr. Sect. F: Struct. Biol. Cryst. Commun. 2008, 64:64-69.
179. Paris G., Ramseyer C., Enescu M. A principal component analysis of the dynamics of subdomains and binding sites in human serum albumin. Biopolymers 2014, 101:561-572.
180. Lu Y., Feng Q., Cui F., Xing W., Zhang G., Yao X. Interaction of 3'-azido-3'-deamino daunorubicin with human serum albumin: investigation by fluorescence spectroscopy and molecular modeling methods. Bioorg. Med. Chem. Lett. 2010, 20:6899-6904.
181. Mao H., Hajduk P.J., Craig R., Bell R., Borre T., Fesik S.W. Rational design of diflunisal analogues with reduced affinity for human serum albumin. J. Am. Chem. Soc. 2001, 123:10429-10435.
182. Sheppard G.S., Wang J., Kawai M., Fidanze S.D., BaMaung N.Y., Erickson S.A., Barnes D.M., Tedrow J.S., Kolaczkowski L., Vasudevan A., Park D.C., Wang G.T., Sanders W.J., Mantei R.A., Palazzo F., Tucker-Garcia L., Lou P., Zhang Q., Park C.H., Kim K.H., Petros A., Olejniczak E., Nettesheim D., Hajduk P., Henkin J., Lesniewski R., Davidsen S.K., Bell R.L. Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of albumin binding. J. Med. Chem. 2006, 49:3832-3849.
183. Wendt M.D., Shen W., Kunzer A., McClellan W.J., Bruncko M., Oost T.K., Ding H., Joseph M.K., Zhang H., Nimmer P.M., Ng S.C., Shoemaker A.R., Petros A.M., Oleksijew A., Marsh K., Bauch J., Oltersdorf T., Belli B.A., Martineau D., Fesik S.W., Rosenberg S.H., Elmore S.W. Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. J. Med. Chem. 2006, 49:1165-1181.
184. Enyedy I.J., Egan W.J. Can we use docking and scoring for hit-to-lead optimization?. J. Comput. Aided Mol. Des. 2008, 22:161-168.
185. Keseru G.M. A virtual high throughput screen for high affinity cytochrome P450cam substrates. Implications for in silico prediction of drug metabolism. J. Comput. Aided Mol. Des. 2001, 15:649-657.
186. Brandt T., Holzmann N., Muley L., Khayat M., Wegscheid-Gerlach C., Baum B., Heine A., Hangauer D., Klebe G. Congeneric but still distinct: how closely related trypsin ligands exhibit different thermodynamic and structural properties. J. Mol. Biol. 2011, 405:1170-1187.
187. Gumede N.J., Singh P., Sabela M.I., Bisetty K., Escuder-Gilabert L., Medina-Hernandez M.J., Sagrado S. Experimental-like affinity constants and enantioselectivity estimates from flexible docking. J. Chem. Inf. Model. 2012, 52:2754-2759.
188. Lexa K.W., Dolghih E., Jacobson M.P. A structure-based model for predicting serum albumin binding. PLoS One 2014, 9:e93323.
189. Chen L., Chen X. Results of molecular docking as descriptors to predict human serum albumin binding affinity. J. Mol. Graph. Model. 2012, 33:35-43.
190. Gambacorti-Passerini C., Barni R., le Coutre P., Zucchetti M., Cabrita G., Cleris L., Rossi F., Gianazza E., Brueggen J., Cozens R., Pioltelli P., Pogliani E., Corneo G., Formelli F., D'Incalci M. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J. Natl. Cancer Inst. 2000, 92:1641-1650.
191. Kretz O., Weiss H.M., Schumacher M.M., Gross G. In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. Br. J. Clin. Pharmacol. 2004, 58:212-216.
192. Hajduk P.J., Mendoza R., Petros A.M., Huth J.R., Bures M., Fesik S.W., Martin Y.C. Ligand binding to domain-3 of human serum albumin: a chemometric analysis. J. Comput. Aided Mol. Des. 2003, 17:93-102.
193. Cruciani G., Pastor M., Clementi S. Handling information from 3D grid maps for QSAR studies. Molecular Modeling and Prediction of Bioactivity 2000, 73-81. Springer, US. K. Gundertofte, F. Jørgensen (Eds.).
194. Li H., Chen Z., Xu X., Sui X., Guo T., Liu W., Zhang J. Predicting human plasma protein binding of drugs using plasma protein interaction QSAR analysis (PPI-QSAR). Biopharm. Drug Dispos. 2011, 32:333-342.
195. Zsila F., Bikadi Z., Malik D., Hari P., Pechan I., Berces A., Hazai E. Evaluation of drug-human serum albumin binding interactions with support vector machine aided online automated docking. Bioinformatics 2011, 27:1806-1813.
196. Singh D.V., Bharti S.K., Agarwal S., Roy R., Misra K. Study of interaction of human serum albumin with curcumin by NMR and docking. J. Mol. Model. 2014, 20:2365.
197. Yeggoni D.P., Gokara M., Manidhar D.M., Rachamallu A., Nakka S., Reddy C.S., Subramanyam R. Binding and molecular dynamics studies of 7-hydroxycoumarin derivatives with human serum albumin and its pharmacological importance. Mol. Pharm. 2014, 11:1117-1131.
198. Zhang H.-x., Liu E. Spectroscopic and molecular modeling investigation on the binding of a synthesized steroidal amide to protein. J. Lumin. 2014, 153:182-187.
199. Rehman M.T., Shamsi H., Khan A.U. Insight into the binding mechanism of imipenem to human serum albumin by spectroscopic and computational approaches. Mol. Pharm. 2014, 11:1785-1797.
200. Lupidi G., Camaioni E., Khalife H., Avenali L., Damiani E., Tanfani F., Scire A. Characterization of thymoquinone binding to human alpha(1)-acid glycoprotein. J. Pharm. Sci. 2012, 101:2564-2573.
201. Huang J.X., Cooper M.A., Baker M.A., Azad M.A., Nation R.L., Li J., Velkov T. Drug-binding energetics of human alpha-1-acid glycoprotein assessed by isothermal titration calorimetry and molecular docking simulations. J. Mol. Recognit. 2012, 25:642-656.
202. Sivertsen A., Brandsdal B.O., Svendsen J.S., Andersen J.H., Svenson J. Short cationic antimicrobial peptides bind to human alpha-1 acid glycoprotein with no implications for the in vitro bioactivity. J. Mol. Recognit. 2013, 26:461-469.
203. Fitos I., Simon A., Zsila F., Mady G., Bencsura A., Varga Z., Orfi L., Keri G., Visy J. Characterization of binding mode of imatinib to human alpha1-acid glycoprotein. Int. J. Biol. Macromol. 2012, 50:788-795.
204. Curry S., Mandelkow H., Brick P., Franks N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat. Struct. Biol. 1998, 5:827-835.
205. Bhattacharya A.A., Grune T., Curry S. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J. Mol. Biol. 2000, 303:721-732.
206. Bhattacharya A.A., Curry S., Franks N.P. Binding of the general anesthetics propofol and halothane to human serum albumin. High resolution crystal structures. J. Biol. Chem. 2000, 275:38731-38738.
207. Petitpas I., Grune T., Bhattacharya A.A., Curry S. Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. J. Mol. Biol. 2001, 314:955-960.
208. Wardell M., Wang Z., Ho J.X., Robert J., Ruker F., Ruble J., Carter D.C. The atomic structure of human methemalbumin at 1.9A. Biochem. Biophys. Res. Commun. 2002, 291:813-819.
209. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., Joseph M.K., Kitada S., Korsmeyer S.J., Kunzer A.R., Letai A., Li C., Mitten M.J., Nettesheim D.G., Ng S., Nimmer P.M., O'Connor J.M., Oleksijew A., Petros A.M., Reed J.C., Shen W., Tahir S.K., Thompson C.B., Tomaselli K.J., Wang B., Wendt M.D., Zhang H., Fesik S.W., Rosenberg S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
210. Yang F., Bian C., Zhu L., Zhao G., Huang Z., Huang M. Effect of human serum albumin on drug metabolism: structural evidence of esterase activity of human serum albumin. J. Struct. Biol. 2007, 157:348-355.
211. Hein K.L., Kragh-Hansen U., Morth J.P., Jeppesen M.D., Otzen D., Moller J.V., Nissen P. Crystallographic analysis reveals a unique lidocaine binding site on human serum albumin. J. Struct. Biol. 2010, 171:353-360.
212. Buttar D., Colclough N., Gerhardt S., MacFaul P.A., Phillips S.D., Plowright A., Whittamore P., Tam K., Maskos K., Steinbacher S., Steuber H. A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions. Bioorg. Med. Chem. 2010, 18:7486-7496.
213. Yamaguchi S., Aldini G., Ito S., Morishita N., Shibata T., Vistoli G., Carini M., Uchida K. Delta12-prostaglandin J2 as a product and ligand of human serum albumin: formation of an unusual covalent adduct at His146. J. Am. Chem. Soc. 2010, 132:824-832.
214. Ryan A.J., Chung C.W., Curry S. Crystallographic analysis reveals the structural basis of the high-affinity binding of iophenoxic acid to human serum albumin. BMC Struct. Biol. 2011, 11:18.
215. He Y., Ning T., Xie T., Qiu Q., Zhang L., Sun Y., Jiang D., Fu K., Yin F., Zhang W., Shen L., Wang H., Li J., Lin Q., Sun Y., Li H., Zhu Y., Yang D. Large-scale production of functional human serum albumin from transgenic rice seeds. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:19078-19083.
216. Wang Y., Luo Z., Shi X., Wang H., Nie L., Huang M. A fluorescent fatty acid probe, DAUDA, selectively displaces two myristates bound in human serum albumin. Protein Sci. 2011, 20:2095-2101.
217. Luo Z., Shi X., Hu Q., Zhao B., Huang M. Structural evidence of perfluorooctane sulfonate transport by human serum albumin. Chem. Res. Toxicol. 2012, 25:990-992.
218. Wang Y., Yu H., Shi X., Luo Z., Lin D., Huang M. Structural mechanism of ring-opening reaction of glucose by human serum albumin. J. Biol. Chem. 2013, 288:15980-15987.
219. Wang Z.M., Ho J.X., Ruble J.R., Rose J., Ruker F., Ellenburg M., Murphy R., Click J., Soistman E., Wilkerson L., Carter D.C. Structural studies of several clinically important oncology drugs in complex with human serum albumin. Biochim. Biophys. Acta 2013, 1830:5356-5374.
220. Sivertsen A., Isaksson J., Leiros H.K., Svenson J., Svendsen J.S., Brandsdal B.O. Synthetic cationic antimicrobial peptides bind with their hydrophobic parts to drug site II of human serum albumin. BMC Struct. Biol. 2014, 14:4.